The success of Sildenafil initially drove a boom for pharma, but recent developments present a complicated scenario for those considering a stake. Off-patent alternatives are eroding earnings, and continued patent https://elodiegqag635812.myparisblog.com/41724175/the-blue-pill-and-the-pharmaceutical-industry-a-volatile-bet